Many of the pharma industry’s biggest companies have over the last week added to their condemnation of Russia’s invasion of Ukraine by declaring a halt to investment in the country and suspension of clinical trials.
Pharma Companies Are Suspending Trials In Russia - But For Practical More Than Ethical Reasons
Sanctions Block Payments For Studies
While pharma is keen to condemn Russia’s aggression, suspension of trials is for practical reasons, and not a punishment of the country’s patients.
More from Clinical Trials
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.